Stem cell transplant for Waldenström macroglobulinemia: An underutilized technique

M. A. Gertz, C. B. Reeder, R. A. Kyle, S. M. Ansell

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenström an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenström macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.

Original languageEnglish (US)
Pages (from-to)1147-1153
Number of pages7
JournalBone Marrow Transplantation
Issue number9
StatePublished - Sep 2012


  • Waldenström macroglobulinemia
  • allogeneic transplant
  • autologous transplant
  • lymphoplasmacytic lymphoma
  • non-Hodgkin lymphoma
  • stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Stem cell transplant for Waldenström macroglobulinemia: An underutilized technique'. Together they form a unique fingerprint.

Cite this